Dynamic BH3 Profiling for Rapid Toxicity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing drug toxicity are limited, particularly in pre-clinical toxicity testing, which can be expensive and unreliable, and lack efficient alternatives for detecting toxic agents in non-cancerous cells.
Innovation Solution
Dynamic BH3 profiling is used to determine the toxicity of agents by measuring the apoptotic sensitivity of non-cancerous cells through percent BH3 domain peptide-induced mitochondrial outer membrane permeabilization (MOMP) and delta percent priming, allowing for rapid detection of toxic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional pre-clinical toxicity testing methods are used, then comprehensive safety assessment can be obtained, but the testing process becomes expensive and time-consuming
Solution Approach 1:
The patent applies preliminary action by performing BH3 profiling on non-cancerous cells before conducting full pre-clinical toxicity testing. This initial screening step predicts which agents are likely to be toxic, allowing researchers to prioritize only those agents for extensive testing, thereby reducing overall testing time and costs while maintaining reliability.
Solution Approach 2:
The patent uses cell-based BH3 profiling as a simplified model (copy) of the complex in vivo toxicity testing system. By measuring apoptotic sensitivity in cultured non-cancerous cells as a surrogate for whole-organism toxicity, the method provides a faster, cheaper alternative that correlates with clinical outcomes, reducing the need for extensive animal testing.
2Reliability
If traditional pre-clinical toxicity testing methods are used, then comprehensive safety assessment can be obtained, but the cost of testing increases
Solution Approach 1:
The patent applies preliminary action by performing BH3 profiling on non-cancerous cells before conducting full pre-clinical toxicity testing. This initial screening step predicts which agents are likely to be toxic, allowing researchers to prioritize only those agents for extensive testing, thereby reducing overall testing time and costs while maintaining reliability.
Solution Approach 2:
The patent uses cell-based BH3 profiling as a simplified model (copy) of the complex in vivo toxicity testing system. By measuring apoptotic sensitivity in cultured non-cancerous cells as a surrogate for whole-organism toxicity, the method provides a faster, cheaper alternative that correlates with clinical outcomes, reducing the need for extensive animal testing.
3Productivity
If dynamic BH3 profiling is used to screen agents, then rapid toxicity detection is achieved, but the method requires new technical procedures
Solution Approach 1:
The patent applies the taking out principle by extracting and measuring a specific molecular event (BH3 domain peptide-induced MOMP) as a standalone readout for toxicity. By focusing on this single apoptotic initiation event rather than measuring multiple downstream effects, the method simplifies the overall assessment process while maintaining predictive accuracy for clinical toxicity.
Solution Approach 2:
The patent applies universality by developing a single BH3 profiling methodology that can be applied to screen any agent against any type of non-cancerous cell. This universal approach replaces the need for multiple specialized toxicity assays, simplifying the technical workflow while enabling broad applicability across different drug development programs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a cost-effective and robust alternative to traditional toxicity testing, enabling the rapid identification of toxic agents and their potential impact on non-cancerous cells, thereby improving the reliability of drug development and safety assessments.
Implementation Method 1
determining a value for percent BH3 domain peptide-induced mitochondrial outer membrane permeabilization (MOMP) in the cells in each of the test aliquots
Data Source
Figure 1A~1D
Figure 1E
Figure 2A~2B
AI summary
The present invention provides methods of assessing toxicity using Dynamic BH3 profiling.